TRCT
CLYM

Tower Research Capital (TRC)’s Climb Bio CLYM Stock Holding History

Tower Research Capital (TRC)’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.2K Sell
2,240
-3,596
-62% -$37.1K ﹤0.01% 3199
2026
Q1 		$40K Buy
5,836
+2,479
+74% +$14.3K ﹤0.01% 2947
2025
Q4 		$13.4K Sell
3,357
-9,887
-75% -$23.7K ﹤0.01% 3406
2025
Q3 		$26.6K Sell
13,244
-858
-6% -$1.59K ﹤0.01% 3051
2025
Q2 		$17.5K Buy
14,102
+5,972
+73% +$7.43K ﹤0.01% 3751
2025
Q1 		$9.92K Buy
8,130
+2,536
+45% +$4.11K ﹤0.01% 3705
2024
Q4 		$10.1K Buy
5,594
+3,037
+119% +$11K ﹤0.01% 3848
2024
Q3 		$13K Sell
2,557
-463
-15% -$3.27K ﹤0.01% 3547
2024
Q2 		$21.5K Sell
3,020
-586
-16% -$3.9K ﹤0.01% 3718
2024
Q1 		$9.88K Buy
3,606
+151
+4% +$415 ﹤0.01% 3779
2023
Q4 		$9.33K Sell
3,455
-441
-11% -$1.15K ﹤0.01% 4407
2023
Q3 		$10.2K Sell
3,896
-858
-18% -$2.34K ﹤0.01% 4134
2023
Q2 		$13.3K Buy
4,754
+1,492
+46% +$4.53K ﹤0.01% 3779
2023
Q1 		$9K Buy
3,262
+2,620
+408% +$9K ﹤0.01% 4558
2022
Q4 		$2K Sell
642
-339
-35% -$1.01K ﹤0.01% 5444
2022
Q3 		$3K Buy
981
+541
+123% +$1.73K ﹤0.01% 5445
2022
Q2 		$1K Sell
440
-1,991
-82% -$9.42K ﹤0.01% 5880
2022
Q1 		$20K Buy
2,431
+1,430
+143% +$13.3K ﹤0.01% 3554
2021
Q4 		$10K Buy
1,001
+510
+104% +$7.6K ﹤0.01% 4625
2021
Q3 		$9K Buy
+491
New +$10.1K ﹤0.01% 4479

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Tower Research Capital (TRC)'s CLYM Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Climb Bio (CLYM) stake by 62% in Q2 2026, selling an estimated $37.1K and leaving 2,240 shares worth $29.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3199.

Tower Research Capital (TRC) first reported a position in CLYM in Q3 2021 and has held it in 20 quarters since. The position peaked at $40K in Q1 2026. 109 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • Tower Research Capital (TRC) held 2,240 shares of Climb Bio worth $29.2K as of Q2 2026.
  • Tower Research Capital (TRC) sold 3,596 Climb Bio shares in Q2 2026, an estimated $37.1K.
  • Climb Bio made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3199 holding.
  • Tower Research Capital (TRC) first reported a position in Climb Bio in Q3 2021 and has held it in 20 quarters since.
  • Tower Research Capital (TRC)'s Climb Bio position peaked at $40K in Q1 2026.
  • 109 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.